Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04429594

Study of the Incidence of SARS-CoV-2 Infection (COVID-19)

This is a prospective observational cohort study that will define the prevalence and incidence of CA-SARS-Cov2 infection using serological and PCR tests in a group of subjects during deconfinement. The team wishes to include approximately 1000 subjects in this study.

The health crisis through containment has also created unprecedented environmental conditions with the very clear decrease in economic activities and a consequent decrease in exposure to the main air pollutants. The aim is therefore to carry out a case-control study in which each subject will be his or her own control in unexposed condition (to PM2.5, PM10, NO...) then exposed (after the recovery of economic activity and the usual levels of air pollutants) and to measure the impact of these pollutants on the immune system and epigenetic markers taking into account seasonality.

The occurrence of infectious, cardiovascular, allergic and autoimmune events will then be measured according to the immunological profiles measured at inclusion.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Coronavirus Infections Coronaviridae Infections Infections Nidovirales Infections RNA Virus Infections Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Nice Hospital

Nice, 06000, France

Location status: Recruiting

Location contact

Barbara SEITZ- POLSKI

CONTACT

[email protected]

334.92.03.55.02

Christian PRADIER

SUB_INVESTIGATOR

barbara SEITZ POLSKI

PRINCIPAL_INVESTIGATOR

sonia BOYER SUAVET

SUB_INVESTIGATOR

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Any major subject, voluntary, exposed to the public from 11 May 2020 informed of the study by partner institutions (Departmental Council 06), affiliated to a social security scheme,

Exclusion criteria

  • Subject protected by law under tutorship or guardianship, or who cannot participate in a clinical study under the terms of Article L. 1121-16 of the French Public Health Code

Treatment and study plan

Blood sampling

Other

blood sampling at J0, M6, M12, M24, M36, M48, M60

Primary outcomes

  1. positive serologies

    Time frame: 12 months

    number of positive serologies

Study contacts

Contact information is provided by the study sponsor or research team.

Barbara SEITZ, MCUPH

CONTACT

[email protected]

334 92 03 55 02

Sponsors and collaborators

Lead sponsor

Centre Hospitalier Universitaire de Nice

Other

Registry information

Official study title

Study of the Incidence of SARS-CoV-2 Infection in the Alpes-Maritimes Department by Analysis of the Specific Humoral and Cellular Response During Deconfinement

Acronym: CovImmune 2

Important dates

Study start
2020
Primary completion
2026
Study completion
2026
First posted
Jun 12, 2020
Registry last updated
Jun 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.